This Article Full Text Full Text (PDF) CME: Take the course for this article: 5-HT3-Receptor Antagonists for the Treatment of Nausea and Vomit... eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goodin, S. Articles by Cunningham, R. Search for Related Content PubMed PubMed Citation Articles by Goodin, S. Articles by Cunningham, R.

5-HT₃-Receptor Antagonists for the Treatment of Nausea and Vomiting: A Reappraisal of Their Side-Effect Profile

^a The Cancer Institute of New Jersey, New Brunswick, New Jersey, USA; ^b UMDNJ/Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA

Correspondence: Susan Goodin, Pharm. D., The Cancer Institute of New Jersey, 195 Albany Street, New Brunswick, New Jersey 08903-2681, USA. Telephone: 732-235-7472; Fax: 732-235-7493; e-mail: goodin{at}umdnj.edu

Nausea and vomiting can cause considerable distress and discomfort to patients undergoing chemotherapy, radiotherapy, or surgery. Several classes of antiemetic agents exist to combat these side effects, though the 5-HT₃-receptor antagonists have become the first-line treatment choice for many cancer patients and are considered the "gold standard" in antiemetic therapy. Compared with the older generation antiemetic drugs, 5-HT₃-receptor antagonists are effective, well tolerated, and associated with few side effects. However, emerging differences among these agents suggest that the incidence and/or intensity of adverse events should not be regarded as a class effect.

The side-effect profile of any supportive care therapy is particularly important in certain subgroups of patients, including pediatric patients and the elderly, as well as those suffering comorbid conditions, such as cardiovascular disease and renal or hepatic impairment. Indeed, dolasetron is associated with cardiovascular effects, and thus, should be used with extreme caution in patients who suffer from or may develop prolongation of cardiac conduction intervals. Ondansetron, on the other hand, is associated with a greater incidence of central nervous system side effects than either dolasetron or ondansetron, and pharmacokinetic parameters are affected in patients with hepatic impairment, thereby requiring dose adjustments.

Clinicians are encouraged to evaluate patients on an individual basis when choosing which 5-HT₃-receptor antagonist to prescribe.

Key Words. 5-HT₃-receptor antagonists • Granisetron • Ondansetron • Dolasetron • Side effects • Emesis

This article has been cited by other articles:

				P. Ellis and N. Dozier Evidence for Equivalent Electrocardiographic Changes Among the 5-HT3 Receptor Antagonists Oncologist, April 1, 2003; 8(2): 216 - 218. [Full Text] [PDF]

				S. Goodin and R. Cunningham In Reply: Evidence for Equivalent Cardiotoxicity of the 5-HT3 Receptor Antagonists Oncologist, April 1, 2003; 8(2): 219 - 221. [Full Text] [PDF]